There were 2,429 press releases posted in the last 24 hours and 431,938 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Theratechnologies annonce des données préliminaires de tolérabilité et d’efficacité provenant de l’essai de détermination de la dose de phase Ib portant sur le sudocétaxel zendusortide mené chez des patientes atteintes d’un cancer de l’ovaire avanc…

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image